Celcuity Q2 2024 Earnings Report

Celcuity EPS Results

• Actual EPS: -$0.62
• Consensus EPS: -$0.71
• Beat/Miss: Beat by +$0.09
• One Year Ago EPS: -$0.66

Celcuity Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Celcuity Announcement Details

• Quarter: Q2 2024
• Date: 8/14/2024
• Time: After Market Closes

Celcuity (NASDAQ:CELC), a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.